Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross

OpenAI’s October 6 release of 722 math solutions signals automation in verifiable research; cryptography’s absence drew Alex’s post-quantum risk warning.Meta’s active memory and 3.6 billion daily users offer reach, but Alex says Muse trails on cost.Alex forecasts the $1.8 billion virtual-cell initiative could yield cures for 5,000 diseases within two to three years, pending FDA acceptance.

Sarah Guo × Elad Gil × Greg Brockman

Brockman says AI is now creating reusable mathematical insight, with almost 400 important open problems solved through unexpected combinations of ideas.Drug development offers the clearest disruption case: a roughly 15-year, $1.5 billion process could accelerate in literature review, simulations, experiments, and regulatory writing, but biological data and long-term outcomes remain constraints.As code approaches near-zero cost, Brockman predicts cybersecurity spending should “far exceed software spending,” while OpenAI’s defender’s window and recurring model-led security testing remain catalysts to monitor.

Ian Quigley × Brandon Anderson × RJ Honicky

Leash’s reported edge is low-cost, carefully characterized data: its ten-person operation developed about 2,000 protein constructs and ran roughly 5,000 screens.On the hardest Kaggle split, none of roughly 2,000 teams beat chance, exposing how poorly models transfer to distant chemistry.Language agents now test hypotheses instantly against measured compounds, but coverage remains limited and potency calibration unfinished.

David Senra × Ben Wilson

Ben Wilson’s stage-four metastatic neuroendocrine carcinoma had an initial one-year prognosis; chemotherapy pushed it back, and he is starting tarlatamab.His framework is breaking trade-offs: NeXT faltered pursuing every priority, while Jobs’s iPod accepted feature gaps for user experience.Tarlatamab’s durability is unclear; clinical trials may follow, and he is exploring a custom mRNA vaccine to enhance it.

Molly O'Shea × Nworah Ayogu

Thrive’s healthcare thesis is that AI may shift bottlenecks from molecule generation to validation, trials, manufacturing, and commercialization.Cadence cites 25% fewer hospitalizations, over-80% more controlled-blood-pressure patients, nearly one-point lower A1C, and $2.5 million in weekly Medicare savings across 100,000+ monitored patients.Neuralink and OpenAI show upside, while clinical processes and manufacturing capacity remain unresolved constraints.

Jonathan Siddharth × Molly O'Shea

Healthcare AI has crossed O'Shea’s threshold for measurable impact, with biological and chemical models, laboratory robotics and simulations targeting drug development’s high failure rates.After a decade building licenses, networks and care infrastructure, Devoted Health tripled in size, halved operating expenses and significantly increased EBITDA, while China’s rising pharmaceutical research share leaves domestic research and regulatory capacity as risks to monitor.

Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross × Ben Lamm

Colossal is now worth over $10 billion with more than four spin-offs, while AI connects fragmented research and addresses 40–60% replication failure through standardized language.That data infrastructure may matter more than the model itself as comparative genomics spans thousands of genomes.Colossal has surpassed 300 edits at over 90% efficiency and is testing 1,000, with large-fragment DNA synthesis and a fully extrauterine mammalian birth within 24 months as catalysts amid ethical and regulatory constraints.

Daniel Ek

Spotify passed 700 million active users and 300 million premium subscribers; Daniel Ek became executive chairman January 1 and returned to building.Neko's $499 unit-economic-positive visit combines 53 blood markers, 6,000 images and clinician review in roughly an hour.Over 100,000 scans found serious, previously undiagnosed conditions in roughly 1% of members; population outcomes and budget effects remain unresolved.

Yiwen × Matteo Franceschetti × Alex Zatarain

Eight Sleep以实时响应而非单纯追踪形成差异化，AI可在睡眠期间调节温度、床头高度和声音。专利、自有传感器与专有数据构成护城河，中国是增长最快市场；FDA睡眠呼吸暂停检测与缓解审批是催化剂，但准确率仍未按任务明确。

Peter Diamandis × Martine Rothblatt

United Therapeutics has four thymus shots on goal, including an FDA-approved xenothymus program and newly acquired Thymmune, making thymic replacement Rothblatt’s “most practical pathway” to LEV in the 2030s.Its xeno-kidney trial is mid-flight, facilities are slated for Rochester in August and Houston in October, and xeno-heart moved to Phase 3 after two patients survived 60 days without heart failure, with IVIVA trials starting in 2028.